{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:14:17Z","timestamp":1771546457912,"version":"3.50.1"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Belumosudil is an orally administered selective ROCK2 inhibitor used in the treatment of chronic graft-vs-host disease. Given that pharmacological activity has been reported to be concentration dependent, factors affecting absorption must be carefully considered. As a weakly basic drug, belumosudil shows pH-dependent solubility, with elevated gastrointestinal pH significantly reducing its solubility and absorption. While proton pump inhibitors are known to markedly decrease the absorption of belumosudil, data on interactions with other acid-suppressing agents remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>This report describes a patient with graft-vs-host disease and bronchiolitis obliterans who was treated with belumosudil alongside various acid-suppressing agents to manage gastrointestinal symptoms and prevent bleeding. The patient sequentially received oral famotidine, intravenous omeprazole, and vonoprazan. Belumosudil was administered once daily after breakfast, while famotidine and vonoprazan were administered after lunch and omeprazole was administered 2 and 9\u2005hours after belumosudil. Trough serum concentrations of belumosudil were 284\u2005ng\/mL (without acid-suppressive therapy), 223\u2005ng\/mL (with famotidine), and 205\u2005ng\/mL (with vonoprazan), while peak concentrations were 1,917\u2005ng\/mL (with omeprazole) and 3,162\u2005ng\/mL (with vonoprazan). Although coadministration with a proton pump inhibitor has been reported to markedly reduce belumosudil exposure, coadministration with the more potent acid suppressant vonoprazan resulted in only a modest decrease in this case.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings suggest that the extent of interaction between acid-suppressive agents and belumosudil may vary depending on individual factors, such as drug timing and interpatient variability in acid suppression. Further research is needed to develop comprehensive management strategies for patients requiring concurrent belumosudil and acid-suppressing therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf270","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T11:44:58Z","timestamp":1759664698000},"page":"e192-e197","source":"Crossref","is-referenced-by-count":0,"title":["Serum belumosudil concentrations in a patient receiving a combination of 3 gastric acid\u2013suppressing agents: A case report"],"prefix":"10.1093","volume":"83","author":[{"given":"Takuya","family":"Araki","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine , Gunma , , Gunma ,","place":["Japan"]},{"name":"and Department of Pharmacy, Gunma University Hospital , Gunma , , Gunma ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Yashima","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine , Gunma , , Gunma ,","place":["Japan"]},{"name":"and Department of Pharmacy, Gunma University Hospital , Gunma , , Gunma ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"Kaneta","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gunma University Hospital , Gunma ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Takei","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gunma University Graduate School of Medicine , Gunma ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gunma University Graduate School of Medicine , Gunma ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Miyazawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gunma University Graduate School of Medicine , Gunma ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gunma University Graduate School of Medicine , Gunma ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Kawano","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gunma University Hospital , Gunma ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Handa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Gunma University Graduate School of Medicine , Gunma ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koujirou","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, Gunma University Graduate School of Medicine , Gunma and , Gunma ,","place":["Japan"]},{"name":"Department of Pharmacy, Gunma University Hospital , Gunma and , Gunma ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"issue":"47","key":"2026021918514277300_zxaf270-B1","doi-asserted-by":"crossref","first-page":"16814","DOI":"10.1073\/pnas.1414189111","article-title":"Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism","volume":"111","author":"Zanin-Zhorov","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"2026021918514277300_zxaf270-B2","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1182\/blood-2015-10-678706","article-title":"Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism","volume":"127","author":"Flynn","year":"2016","journal-title":"Blood"},{"issue":"14","key":"2026021918514277300_zxaf270-B3","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s40265-021-01593-z","article-title":"Belumosudil: first approval","volume":"81","author":"Blair","year":"2021","journal-title":"Drugs"},{"issue":"7","key":"2026021918514277300_zxaf270-B4","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1002\/cpdd.1085","article-title":"Absolute bioavailability, mass balance, and metabolic profiling assessment of [14C]-belumosudil in healthy men: a phase 1, open-label, 2-part study","volume":"11","author":"Schueller","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"7","key":"2026021918514277300_zxaf270-B5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/cpdd.1082","article-title":"A phase 1 pharmacokinetic drug interaction study of belumosudil coadministered with CYP3A4 inhibitors and inducers and proton pump inhibitors","volume":"11","author":"Schueller","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026021918514277300_zxaf270-B6","author":"Rezurock"},{"key":"2026021918514277300_zxaf270-B7","author":"Rezurock"},{"key":"2026021918514277300_zxaf270-B8","article-title":"Product monograph","author":"Rezurock","year":"2024","journal-title":"Amgen Canada"},{"issue":"19","key":"2026021918514277300_zxaf270-B9","doi-asserted-by":"crossref","first-page":"e38369","DOI":"10.1016\/j.heliyon.2024.e38369","article-title":"Comprehensive chromatographic analysis of belumosudil and its degradation products: development, validation, and in silico toxicity assessment","volume":"10","author":"Ali","year":"2024","journal-title":"Heliyon"},{"issue":"23","key":"2026021918514277300_zxaf270-B10","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2026021918514277300_zxaf270-B11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12916-024-03348-5","article-title":"A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China","volume":"22","author":"Wang","year":"2024","journal-title":"BMC Med"},{"issue":"2","key":"2026021918514277300_zxaf270-B12","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/clpt.1987.136","article-title":"The effect of various dose regimens of famotidine on basal nocturnal and meal-stimulated gastric secretion","volume":"42","author":"Ryan","year":"1987","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2026021918514277300_zxaf270-B13","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/apt.13325","article-title":"Acid-inhibitory effects of vonoprazan 20\u2005mg compared with esomeprazole 20\u2005mg or rabeprazole 10\u2005mg in healthy adult male subjects\u2014a randomised open-label cross-over study","volume":"42","author":"Sakurai","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"2026021918514277300_zxaf270-B14","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/1756283X17705329","article-title":"A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20\u2005mg and 40\u2005mg) in patients with proton-pump inhibitor-resistant erosive esophagitis","volume":"10","author":"Iwakiri","year":"2017","journal-title":"Therap Adv Gastroenterol"},{"issue":"7","key":"2026021918514277300_zxaf270-B15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/cpdd.1083","article-title":"Phase 1 studies to evaluate the food effect and relative bioavailability of tablet and capsule formulations of belumosudil in healthy adult subjects","volume":"11","author":"Schueller","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"2026021918514277300_zxaf270-B16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.clpt.2006.08.010","article-title":"Initial 48-hour acid inhibition by intravenous infusion of omeprazole, famotidine, or both in relation to cytochrome P450 2C19 genotype status","volume":"80","author":"Sugimoto","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"2026021918514277300_zxaf270-B17","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1053\/gast.2000.16515","article-title":"Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism","volume":"119","author":"Sagar","year":"2000","journal-title":"Gastroenterology"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf270\/64540856\/zxaf270.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/5\/e192\/64540856\/zxaf270.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/5\/e192\/64540856\/zxaf270.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:51:51Z","timestamp":1771545111000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/5\/e192\/8277123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":17,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10,8]]},"published-print":{"date-parts":[[2026,2,20]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf270","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3,1]]},"published":{"date-parts":[[2025,10,8]]}}}